Navigation Links
Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers

se 2 Trials

Poniard anticipates initiating the Phase 2 components of the CRC and HRPC trials in the third quarter of 2007.

The Phase 2 CRC trial will include patients newly diagnosed with metastatic disease and will evaluate the safety and efficacy of picoplatin when combined with fluorouracil and leucovorin (FOLPI) and administered biweekly compared with oxaliplatin (Eloxatin(R)) at 85 mg/m2 combined with fluorouracil and leucovorin (FOLFOX). The objective of this multi-center, double-blind, randomized Phase 2 CRC trial of approximately 140 patients is to demonstrate that picoplatin is a neuropathy-sparing platinum that has an improved side effect profile compared to oxaliplatin, enabling a larger randomized Phase 3 CRC trial that has the potential to demonstrate superior safety and efficacy compared to FOLFOX.

The objective of the Phase 2 HRPC trial is to position picoplatin as the preferred platinum in combination with docetaxel plus prednisone and improve on the efficacy of docetaxel as a single agent plus prednisone. This multi- center, open-label, single-arm trial of approximately 30 patients is designed to demonstrate superior efficacy when picoplatin is administered with docetaxel plus prednisone every three weeks in the first-line setting.

About Picoplatin

Picoplatin, the Company's lead product candidate, is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. In addition to the ongoing Phase 1/2 clinical trials of intravenous picoplatin in CRC and HRPC, Poniard is evaluating intravenous picoplatin in an ongoing Phase 2 clinical trial in small cell lung cancer (SCLC). On May 1, 2007, the Company announced treatment of the first patient in its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of intravenous picoplatin in SCLC, which is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA). Poniard re
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/24/2014)... LOS ANGELES , July 24, 2014 /PRNewswire/ ... medical devices, announced today that after two weeks ... experts throughout the European Union, it gained substantial ... (sub-epidermal moisture) and the clinical utility of BBI,s ... surveys, over 90 percent of the respondents drawn ...
(Date:7/24/2014)... WHIPPANY, N.J. , July 24, 2014 /PRNewswire-USNewswire/ ... Phase III trial that evaluated a 15% foam ... the topical treatment of inflammatory papules and pustules ... potential treatment option to complement the currently available ... disease causing inflammatory lesions (papules and pustules) as ...
(Date:7/24/2014)... , July 24, 2014  Market Diagnostics International ... IVD Insights™ LabFile , a data resource that ... clinical laboratory universe and identifying target In Vitro ... proprietary database that provides IVD manufacturers with accurate ... relying on clear and consistent definitions of laboratory ...
Breaking Medicine Technology:Bruin Biometrics Secures Support of EU Scientific Community for its SEM Scanner Technology 2Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 2Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 3MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2
... Va., June 22 With today,s announcement that the Pharmaceutical ... grant some $80 billion in discounts to Medicare beneficiaries over ... costs, the Healthcare Compliance Packaging Council (HCPC) noted that far ... to help people take their prescription drugs properly. ...
... /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE ... that a new corporate presentation is available for review ... . The presentation includes information on ... treat swine and other influenza viruses using its L.E.A.P.S.(TM) ...
Cached Medicine Technology:HCPC Calls for Greater Healthcare Savings Through Improved Adherence to Prescription Drug Regimens 2HCPC Calls for Greater Healthcare Savings Through Improved Adherence to Prescription Drug Regimens 3
(Date:7/24/2014)... 2014 National Analysts Worldwide, the Philadelphia-headquartered ... will operate globally under the name, NAXION , ... Employee Stock Ownership Plan (ESOP) organization led by majority ... . The firm guides market strategy in target ... , Said McDonald, “We wanted our name to better ...
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & ... (Swine, Poultry, Cattle, Pets, Aquaculture, and Others) - Global ... feed palatability enhancers & modifiers market with an analysis ... value, of types of feed flavors, sweeteners, and text ... figures spread through 275 pages and in-depth TOC on ...
(Date:7/24/2014)... and faster, according to a new study published in ... to tackle melanoma, the most deadly form of skin ... of Manchester found that some melanoma cells are particularly ... surrounding tissue, while other melanoma cells are the opposite ... tumour, the faster growing cells ,piggy-back, along with the ...
(Date:7/24/2014)... The Biofeedback Federation of ... distribution agreement with game development company Zukor Interactive. ... groups to offer Zukor's Grind , a ... neurofeedback in European and international markets. , Zukor's ... to be used as a biofeedback/neurofeedback training tool. ...
(Date:7/24/2014)... WEDNESDAY, July 23, 2014 (HealthDay News) -- Even though its ... best known as Tylenol -- does not help treat lower ... The researchers found the drug was no more effective than ... acute lower back pain. Besides showing no effect in ... help in improving sleep woes tied to back pain, nor ...
Breaking Medicine News(10 mins):Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4Health News:Piggy-backing cells hold clue to skin cancer growth 2Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 2Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 3Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 2Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 3
... ... year’s edition of The Leading Physicians of the World. With a long track record of ... of the World wanted to honor the specialty so integral to the surgical team; anesthesiology. ... (PRWEB) June 26, 2010 ...
... ... by whiplash injury should be made aware of their legal entitlement to file a whiplash ... ... leading whiplash injury claims lawyers, is today warning of the need for greater awareness of ...
... ... Haitian children, mostly refugees and orphans who go all day without eating. Shelene Bryan and ... ... and her Skip1 team of volunteers were deep inside Haiti and the Dominican Republic delivering ...
... ... a renewable resource. , ... June 26, 2010 -- Laser and copier toners use over 146,000,000 gallons of oil per ... or Forestry products, therefore, eliminating the need for petroleum products. The term bio-product is ...
... studying and treating disease and for the practice of ... the cells that may one day be transplanted into ... studies going on worldwide, scientists at the UCLA Broad ... X chromosome inactivation take place in very early passages ...
... By Maryann Mott HealthDay Reporter , FRIDAY, June ... chuckle out of watching their dog sleep while its paws race ... in dreamland, and scientists say they were right: Pets do ... of past events replay in their minds much the same way ...
Cached Medicine News:Health News:The International Association of Anesthesiologists Places its Top Doctors in the Renowned Medical Publication, The Leading Physicians of the World. 2Health News:The International Association of Anesthesiologists Places its Top Doctors in the Renowned Medical Publication, The Leading Physicians of the World. 3Health News:Whiplash Claims Warns on Awareness of Personal Injury Compensation Entitlement 2Health News:Shelene Bryan and Skip1.org Help Build Kitchen for Haitian Orphans 2Health News:Great Office Buys Announces the Addition of Elite Brand Bio-Based Toners to their Product Line 2Health News:Chromosomal variations found in early passage female embryonic stem cells 2Health News:Chromosomal variations found in early passage female embryonic stem cells 3Health News:Where Do Pets Go When They Dream? 2Health News:Where Do Pets Go When They Dream? 3
... heavy duty, controlled stretch knee support that ... allowing full range of motion. The ... the knee, and help to keep the ... This is an excellent support for ...
... breathable foam. Three piece design for precise ... loop closures. Lightweight rigid posterior stays with ... with optional hot and cold therapy Gel ... pain cycle by providing cold therapy to ...
... Scoring: , One of the outstanding features ... our patented Three-Dimensional Molding Technology. , This ... brace which effectively controls the bunching and ... comfort to the wearer. , ...
... new padding system from Innovation Sports. Exceptionally ... contours to the unique anatomy of each ... Gel Fit's proprietary Octogrip™ Anti-Slip System improves ... when the brace is strapped on. Gel ...
Medicine Products: